Fig. 8
Angiogenic effects of PRTN3 and bevacizumab sensitivity. Tube formation assay was performed using the endothelial tube formation kit. PRTN3 was added at a final concentration of 0-1000 ng/mL, and Bev was added at a final concentration of 0-2.5 mg/mL to 2.5×104 cells of human umbilical vein endothelial cells per each well. After incubation at 37℃ and 5% CO2 for 2 h, the number of branches and tube area were evaluated. (a) Representative images of tube formation assay. Scale bar: 100 µm. (b) Number of branching points. The number of branches is increased in a PRTN3 dose-dependent manner. The number of branches is decreased with the administration of bevacizumab. PRTN3 administration increased the number of branches in a dose-dependent manner regardless of bevacizumab administration. (c) Tube area. The results are the same as those for the number of branches. *P<0.05